Fisetin: The Most Promising Natural Senolytic

Senescent cells are cells that have permanently stopped dividing—often in response to DNA damage, oxidative stress, or telomere shortening—but have not been cleared by the immune system. Instead of dying, they persist in tissues and secrete a cocktail of inflammatory cytokines, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP). This chronic low-grade inflammation damages surrounding tissue, impairs stem cell function, and creates a microenvironment that promotes further cellular dysfunction. Senescent cells accumulate progressively with age, and their accumulation is one of the best-characterized hallmarks of aging with causal evidence from transgenic mouse experiments: selectively clearing senescent cells in aged mice extends median lifespan by 17–35% and dramatically improves healthspan.

The therapeutic strategy of selectively eliminating senescent cells—senolytic therapy—has become one of the most active areas in longevity medicine. Fisetin is the most compelling natural compound with senolytic activity identified to date.

How Fisetin Works as a Senolytic

Senescent cells survive despite being dysfunctional because they upregulate anti-apoptotic (pro-survival) pathways—particularly BCL-2 family proteins and the PI3K/AKT pathway—that protect them from programmed cell death. Senolytics exploit this: they transiently inhibit these survival pathways, selectively inducing apoptosis in senescent cells while leaving normal cells relatively unharmed.

Fisetin is a flavonol found at the highest concentrations in strawberries, but also present in apples, persimmons, grapes, onions, and cucumbers. At the molecular level, fisetin inhibits BCL-2 and BCL-XL (senescent cell survival proteins), reduces SASP through multiple mechanisms including PI3K/AKT inhibition, and has intrinsic anti-inflammatory activity through NF-kB suppression.

Critically, fisetin's senolytic activity was not the original reason it was studied—it was first investigated as a neuroprotective compound for its ability to activate sirtuins and BDNF signaling. The senolytic discovery emerged from a systematic screen of flavonoids by researchers at the Mayo Clinic.

The Mayo Clinic Research

In a landmark 2018 paper published in EBioMedicine, researchers at the Mayo Clinic's Kirkland lab systematically tested 10 flavonoids for senolytic activity in human cells and aged mice. Fisetin was identified as the most potent senolytic flavonoid tested—significantly outperforming quercetin, another flavonoid that receives attention in the senolytic space.

In aged mice, fisetin reduced senescent cell burden in multiple tissues, improved tissue function, reduced inflammatory markers, improved cognitive performance, and extended both median and maximum lifespan. The effect size was notable: supplementation starting in late life (equivalent to roughly 75–80 years in human terms) still produced meaningful lifespan extension.

The SenNet Consortium, a large NIH-funded initiative to map senescent cells across human tissues and ages, has provided additional context for these findings by characterizing senescent cell abundance in different human tissues and validating the pro-inflammatory SASP phenotype of senescent cells in human tissue samples.

Fisetin vs. Quercetin

Quercetin is the most commonly discussed natural senolytic—it appears in numerous supplement formulations and was the first natural compound shown to have senolytic activity (in combination with dasatinib, a cancer drug, in the seminal 2015 Kirkland lab paper). However, the Mayo Clinic comparison study found fisetin substantially more potent than quercetin as a senolytic in multiple assays.

Quercetin also has very low and variable bioavailability (under 2% when taken alone), though this can be improved with quercetin phytosome formulations or co-administration with bromelain. Fisetin has better intrinsic bioavailability than quercetin and shows better tissue penetration in animal studies.

This does not mean quercetin has no role—the dasatinib + quercetin (D+Q) combination remains the most clinically studied senolytic protocol and is in multiple human trials. But for natural senolytic supplementation, fisetin has a stronger evidence base than quercetin alone.

The Intermittent Dosing Protocol

Senolytics are conceptually different from most supplements: they are not designed for daily consumption. The logic is that senescent cells accumulate over months to years, so you do not need to continuously suppress them—you need intermittent "clearing" pulses that eliminate accumulated senescent cells. The immune system then maintains lower senescent cell burden between doses.

The animal research has typically used high doses for 2–3 consecutive days. Translated to humans, the commonly discussed protocol is approximately 20mg/kg bodyweight for 2–3 consecutive days, repeated monthly or quarterly. For a 75kg person, this equates to approximately 1500mg daily for 2–3 days.

These are pharmacological doses—far exceeding what food can provide (a serving of strawberries contains roughly 0.16mg of fisetin). This is an important distinction: the concentrations required for senolytic activity are drug-like, not nutritional. You cannot eat enough strawberries to achieve senolytic effects.

Human Evidence: Early Stage but Coming

Human data for fisetin specifically is in its early phase. A Mayo Clinic pilot trial in patients with diabetes-related kidney disease found that a 2-day high-dose fisetin protocol reduced circulating levels of p21 and other senescent cell markers. A larger trial in older adults (AFFIRM-LITE) is ongoing. Initial human safety data appears reassuring, though formal efficacy data in healthy aging populations is not yet published.

FAQ

Q: Is it safe to take fisetin at high doses? Fisetin has an excellent safety profile in animal studies even at high doses. Limited human safety data exists at senolytic doses (1000–2000mg). The intermittent protocol (2–3 days per month) minimizes exposure. Fisetin can inhibit CYP enzymes that metabolize some drugs—people on medications should check for interactions.

Q: Why not just eat more strawberries? Strawberries are healthy, but fisetin content is too low to achieve senolytic concentrations through diet. Achieving 1000–1500mg of fisetin from strawberries would require eating roughly 6–10 kg of strawberries per day. Supplementation is the only practical route to senolytic doses.

Q: How do I know if fisetin is working? There are no reliable home tests for senescent cell burden. Inflammatory biomarkers (IL-6, TNF-alpha, CRP) may decline with effective senolytic therapy and can be measured through blood tests. Research-grade tests for p16 and p21 expression in circulating cells are used in clinical trials but not widely available clinically.

Track your supplements in Optimize.